Lupus is a chronic autoimmune disease that affects millions of people worldwide. The lupus therapeutic market is expected to grow rapidly in the coming years due to the increasing prevalence of lupus, the growing demand for effective treatments, and the emergence of new therapies. The market is driven by factors such as increasing R&D investment in lupus treatments, rising awareness about the disease, and favorable government initiatives. However, the high cost of treatment, lack of standardized diagnostic tests, and the complexity of the disease may pose challenges to the growth of the market. Nonetheless, the potential benefits of new and emerging therapies for lupus, including biologics, immunosuppressants, and antimalarials, make it an exciting and rapidly evolving field with significant potential for growth.
The global Lupus Therapeutic Market is estimated to be valued at US$ 2,795.2 million in 2022 and is expected to exhibit a CAGR of 8.6% over the forecast period (2022-2030).
Top Companies in the Lupus Therapeutic Industry:
1. Hikma Pharmaceuticals PLC
Founded in 1978, Hikma Pharmaceuticals is a multinational pharmaceutical company headquartered in London, UK. It operates in over 50 countries worldwide, with a focus on the Middle East and North Africa (MENA) region. Hikma develops, manufactures, and markets a broad range of generic and branded pharmaceutical products, including treatments for lupus. In January, 2023 Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new exclusive licensing agreement with Celltrion Healthcare Co., Ltd, a global biopharmaceutical company.
2. Lupus Therapeutics
Lupus Therapeutics is a subsidiary of the Lupus Research Alliance, a non-profit organization focused on advancing research into lupus. The company was founded in 2016 and is headquartered in New York City, USA. Lupus Therapeutics collaborates with leading researchers and pharmaceutical companies to develop new treatments for lupus and bring them to market.
3. Dr. Reddy's Laboratories Ltd.
Founded in 1984, Dr. Reddy's Laboratories is a multinational pharmaceutical company headquartered in Hyderabad, India. The company operates in over 25 countries worldwide and specializes in the development, manufacture, and marketing of generic and branded pharmaceuticals, including treatments for lupus. In February, 2023 Dr. Reddy’s announced that it has entered into a definitive agreement to acquire the U.S. generic prescription product portfolio of Salisbury, Australia, based Mayne Pharma Group Limited
4. GlaxoSmithKline plc
Founded in 2000, GlaxoSmithKline is a British multinational pharmaceutical company headquartered in Brentford, UK. It operates in over 100 countries worldwide and focuses on the development, manufacture, and marketing of pharmaceuticals, vaccines, and consumer healthcare products. GSK has a portfolio of treatments for lupus. In March, 2023 GSK plc and SCYNEXIS, Inc. announced they have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a US FDA approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC (RVVC).
5. Amgen Inc
Founded in 1980, Amgen is a multinational biopharmaceutical company headquartered in Thousand Oaks, California, USA. The company operates in over 100 countries worldwide and focuses on the development, manufacture, and marketing of biologic and biosimilar products, including treatments for lupus.
6. Novartis AG
Founded in 1996, Novartis is a multinational pharmaceutical company headquartered in Basel, Switzerland. It operates in over 140 countries worldwide and focuses on the development, manufacture, and marketing of pharmaceuticals, eye care products, and generics, including treatments for lupus. In March, 2023 Sandoz, the global leader in off-patent medicines, has signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine® (micafungin sodium, Funguard® in Japan) from Astellas.
7. Sanofi
Founded in 1973, Sanofi is a French multinational pharmaceutical company headquartered in Paris, France. It operates in over 170 countries worldwide and focuses on the development, manufacture, and marketing of pharmaceuticals, vaccines, and consumer healthcare products, including treatments for lupus. In March, 2023 Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded Biopharmaceutical Company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc., for $25.00 per share in cash, representing an equity value of approximately $2.9 billion.
8. UCB S.A.
Founded in 1928, UCB is a Belgian multinational biopharmaceutical company headquartered in Brussels, Belgium. It operates in over 40 countries worldwide and specializes in the development, manufacture, and marketing of biologic and small molecule treatments for severe diseases, including lupus.
9. ImmuPharma PLC
Founded in 1999, ImmuPharma is a biopharmaceutical company headquartered in London, UK. It specializes in the development of novel immunotherapeutic drugs for the treatment of autoimmune diseases, including lupus. The company operates in multiple countries worldwide.
10. Bayer AG
Founded in 1863, Bayer is a German multinational pharmaceutical and life sciences company headquartered in Leverkusen, Germany. It operates in over 90 countries worldwide and focuses on the development, manufacture, and marketing of pharmaceuticals, consumer healthcare products, and agricultural products, including treatments for lupus.
11. Merck & Co., Inc.
Founded in 1891, Merck is a multinational pharmaceutical company headquartered in Kenilworth, New Jersey, USA. The company operates in over 140 countries worldwide and focuses on the development, manufacture, and marketing of pharmaceuticals and vaccines, including treatments for lupus. In November, 2021 Merck & Co. Inc. announced that the US Food and Drug Administration (FDA) had granted the company's investigational HIV-1 capsid inhibitor, MK-8718, Breakthrough Therapy designation for the treatment of people living with HIV-1 who have highly resistant strains of the virus.
12. Aurinia Pharmaceuticals Inc.
Founded in 2013, Aurinia Pharmaceuticals is a Canadian biopharmaceutical company headquartered in Victoria, British Columbia, Canada.
*Definition-Lupus therapeutic refers to the range of treatments used to manage the symptoms of lupus, an autoimmune disease that causes inflammation and damage to various parts of the body.
